Financial Comparison
Johnson & Johnson vs Merck & Co., Inc.
Click a ticker to view the full analysis.
In short
Johnson & Johnson is the more profitable of the two, keeping 28.5% of revenue as net profit against 28.1% for Merck & Co., Inc. Merck & Co., Inc. trades at the higher trailing P/E (113.0× vs 29.7× for Johnson & Johnson), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Johnson & Johnson and 1 for Merck & Co., Inc.
Based on filings for periods ending 28 Jun 2026 (JNJ) and 30 Jun 2026 (MRK) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. JNJ shown solid · MRK shown dashed. Not financial advice.
| Metric | JNJ | MRK |
|---|---|---|
| Price | $256.48 | $142.38 |
| Market Cap | $618.1B | $351.3B |
| P/E (TTM) | 29.7x | 113.0x |
| P/B | 7.3x | 8.4x |
| Beta | 0.21 | 0.22 |
| Div Yield | 2.03% | 2.34% |
| Revenue (TTM) | $94.2B | $65.0B |
| Net Income | $26.8B | $18.3B |
| Gross Margin | 67.9% | — |
| Risk Flags | 1 flag | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.